Colorado Senate Bill SB066

Colorado 2025 Regular Session

• Introduced: 1/22/25
• Refer: 1/22/25
• Failed: 2/26/25

Caption

State Contracts with Opioid Antagonist Businesses

Impact

The bill is designed to enhance the integrity of the state’s opioid antagonist bulk purchase fund. By ensuring that only reputable distributors are involved in the purchase and distribution process, the legislation seeks to prevent the state from inadvertently supporting entities that have previously caused harm through irresponsible distribution practices. In doing so, it strives to improve public trust in state efforts to combat the opioid epidemic and ensure the effective allocation of resources for opioid overdose prevention.

Summary

Senate Bill 25-066 aims to regulate state contracts with opioid antagonist medication distributors in Colorado. The bill establishes guidelines for the bulk purchase of opioid antagonists by prohibiting the state from contracting with certain distributors. Specifically, it excludes any distributor found liable for contributing to an opioid-related overdose or those tied to settlements or penalties related to opioid distribution. This change is intended to ensure that public health initiatives are supported by companies that have not contributed to the opioid crisis.

Contention

Notable points of contention surrounding SB066 may arise from the competitive selection process mandated by the bill. While supporters claim that such measures are necessary to uphold accountability, opponents might argue that this could limit the availability of opioid antagonists, particularly if only a few distributors are deemed eligible under the stringent criteria. Additionally, there could be concerns about the bill's implementation and how it might impact future partnerships with pharmaceutical companies that play a role in addressing substance use disorders.